S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:ONVO

Organovo (ONVO) Stock Price, News & Analysis

$1.02
0.00 (0.00%)
(As of 03/1/2024 ET)
Today's Range
$1.01
$1.04
50-Day Range
$0.90
$1.17
52-Week Range
$0.89
$2.33
Volume
33,924 shs
Average Volume
113,486 shs
Market Capitalization
$10.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Organovo MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Organovo in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.74) to ($1.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.21 out of 5 stars

Medical Sector

934th out of 951 stocks

Biological Products, Except Diagnostic Industry

157th out of 158 stocks


ONVO stock logo

About Organovo Stock (NASDAQ:ONVO)

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

ONVO Stock Price History

ONVO Stock News Headlines

StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Organovo Holdings Inc ONVO
ONVO Continues Progress
Organovo: Fiscal Q3 Earnings Snapshot
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ONVO, FATH and BYU among mid-day movers
ONVO Organovo Holdings, Inc.
Organovo (NASDAQ: ONVO)
Organovo Announces FXR Program
See More Headlines
Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2019
Today
3/02/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
7/11/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Net Income
$-17,260,000.00
Net Margins
-4,061.12%
Pretax Margin
-7,885.54%

Debt

Sales & Book Value

Annual Sales
$370,000.00
Book Value
$0.62 per share

Miscellaneous

Free Float
9,638,000
Market Cap
$10.24 million
Optionable
Optionable
Beta
0.91
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Keith E. Murphy (Age 52)
    Company Secretary & Executive Chairman
    Comp: $626.24k
  • Ms. Vaidehi Joshi (Age 38)
    Director of Discovery Biology & Director
    Comp: $91.4k
  • Mr. Thomas P. Hess CPA (Age 60)
    MBA, President & CFO
  • Dr. Curtis M. Tyree Ph.D.
    Senior Vice President of Strategy & Business Development














ONVO Stock Analysis - Frequently Asked Questions

How have ONVO shares performed in 2024?

Organovo's stock was trading at $1.11 on January 1st, 2024. Since then, ONVO stock has decreased by 8.1% and is now trading at $1.02.
View the best growth stocks for 2024 here
.

Are investors shorting Organovo?

Organovo saw a increase in short interest in February. As of February 15th, there was short interest totaling 407,000 shares, an increase of 29.4% from the January 31st total of 314,600 shares. Based on an average daily trading volume, of 179,000 shares, the short-interest ratio is currently 2.3 days.
View Organovo's Short Interest
.

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024.
View our ONVO earnings forecast
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) issued its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.00). The medical research company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.77 million. Organovo had a negative trailing twelve-month return on equity of 182.88% and a negative net margin of 4,061.12%.

When did Organovo's stock split?

Shares of Organovo reverse split before market open on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

Who are Organovo's major shareholders?

Organovo's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.52%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Gobel and Douglas Jay Cohen.
View institutional ownership trends
.

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONVO) was last updated on 3/2/2024 by MarketBeat.com Staff